Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Non-NAD-like PARP-1 inhibitors in prostate cancer treatment.

Karpova Y, Wu C, Divan A, McDonnell ME, Hewlett E, Makhov P, Gordon J, Ye M, Reitz AB, Childers WE, Skorski T, Kolenko V, Tulin AV.

Biochem Pharmacol. 2019 Mar 15. pii: S0006-2952(19)30107-8. doi: 10.1016/j.bcp.2019.03.021. [Epub ahead of print]

PMID:
30880062
2.

BRCA1 deficiency and synthetic lethality in leukemias; not only gene mutation matters.

Piwocka K, Podszywałow-Bartnicka P, Skorski T.

Postepy Biochem. 2018 Oct 15;64(2):141-147. doi: 10.18388/pb.2018_124.

3.

Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent.

Toma M, Witusik-Perkowska M, Szwed M, Stawski R, Szemraj J, Drzewiecka M, Nieborowska-Skorska M, Radek M, Kolasa P, Matlawska-Wasowska K, Sliwinski T, Skorski T.

Oncotarget. 2018 Dec 7;9(96):36867-36877. doi: 10.18632/oncotarget.26409. eCollection 2018 Dec 7.

4.

Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia.

Nieborowska-Skorska M, Maifrede S, Ye M, Toma M, Hewlett E, Gordon J, Le BV, Sliwinski T, Zhao H, Piwocka K, Valent P, Tulin AV, Childers W, Skorski T.

Leuk Lymphoma. 2019 Apr;60(4):1098-1101. doi: 10.1080/10428194.2018.1520988. Epub 2018 Oct 2. No abstract available.

PMID:
30277116
5.

PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions.

Podszywalow-Bartnicka P, Maifrede S, Le BV, Nieborowska-Skorska M, Piwocka K, Skorski T.

Leuk Lymphoma. 2019 Jan;60(1):262-264. doi: 10.1080/10428194.2018.1471602. Epub 2018 Jun 22. No abstract available.

PMID:
29932782
6.

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.

Sullivan-Reed K, Bolton-Gillespie E, Dasgupta Y, Langer S, Siciliano M, Nieborowska-Skorska M, Hanamshet K, Belyaeva EA, Bernhardy AJ, Lee J, Moore M, Zhao H, Valent P, Matlawska-Wasowska K, Müschen M, Bhatia S, Bhatia R, Johnson N, Wasik MA, Mazin AV, Skorski T.

Cell Rep. 2018 Jun 12;23(11):3127-3136. doi: 10.1016/j.celrep.2018.05.034.

7.

Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.

Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik MA, Huang J, Skorski T.

Blood. 2018 Jul 5;132(1):67-77. doi: 10.1182/blood-2018-02-834895. Epub 2018 May 21.

PMID:
29784639
8.

Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage.

Caruso LB, Martin KA, Lauretti E, Hulse M, Siciliano M, Lupey-Green LN, Abraham A, Skorski T, Tempera I.

Oncotarget. 2018 Jan 24;9(12):10585-10605. doi: 10.18632/oncotarget.24291. eCollection 2018 Feb 13.

9.

DNA Double Strand Break Repair - Related Synthetic Lethality.

Toma M, Skorski T, Sliwinski T.

Curr Med Chem. 2019;26(8):1446-1482. doi: 10.2174/0929867325666180201114306.

PMID:
29421999
10.

MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.

Maifrede S, Martinez E, Nieborowska-Skorska M, Di Marcantonio D, Hulse M, Le BV, Zhao H, Piwocka K, Tempera I, Sykes SM, Skorski T.

Blood Adv. 2017 Aug 9;1(19):1467-1472. doi: 10.1182/bloodadvances.2017006247. eCollection 2017 Aug 22.

11.

Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia.

Di Marcantonio D, Martinez E, Sidoli S, Vadaketh J, Nieborowska-Skorska M, Gupta A, Meadows JM, Ferraro F, Masselli E, Challen GA, Milsom MD, Scholl C, Fröhling S, Balachandran S, Skorski T, Garcia BA, Mirandola P, Gobbi G, Garzon R, Vitale M, Sykes SM.

Clin Cancer Res. 2018 Feb 1;24(3):608-618. doi: 10.1158/1078-0432.CCR-17-2684. Epub 2017 Nov 10.

12.

Drugging DNA repair to target T-ALL cells.

Dasgupta Y, Golovine K, Nieborowska-Skorska M, Luo L, Matlawska-Wasowska K, Mullighan CG, Skorski T.

Leuk Lymphoma. 2018 Jul;59(7):1746-1749. doi: 10.1080/10428194.2017.1397662. Epub 2017 Nov 8. No abstract available.

13.

Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.

Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, Wasik M, Koschmieder S, Green TR, Skoda RC, Skorski T.

Blood. 2017 Dec 28;130(26):2848-2859. doi: 10.1182/blood-2017-05-784942. Epub 2017 Oct 17.

14.

IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.

Maifrede S, Martin K, Podszywalow-Bartnicka P, Sullivan-Reed K, Langer SK, Nejati R, Dasgupta Y, Hulse M, Gritsyuk D, Nieborowska-Skorska M, Lupey-Green LN, Zhao H, Piwocka K, Wasik MA, Tempera I, Skorski T.

Mol Cancer Res. 2017 Aug;15(8):967-972. doi: 10.1158/1541-7786.MCR-16-0468. Epub 2017 Jun 20.

15.

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T.

J Clin Invest. 2017 Jun 1;127(6):2392-2406. doi: 10.1172/JCI90825. Epub 2017 May 8.

16.

Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.

Mukherjee K, Sha X, Magimaidas A, Maifrede S, Skorski T, Bhatia R, Hoffman B, Liebermann DA.

Oncotarget. 2017 Feb 14;8(7):10809-10821. doi: 10.18632/oncotarget.14580.

17.

Transformed Root Extract of Leonurus sibiricus Induces Apoptosis through Intrinsic and Extrinsic Pathways in Various Grades of Human Glioma Cells.

Sitarek P, Skała E, Toma M, Wielanek M, Szemraj J, Skorski T, Białas AJ, Sakowicz T, Kowalczyk T, Radek M, Wysokińska H, Śliwiński T.

Pathol Oncol Res. 2017 Jul;23(3):679-687. doi: 10.1007/s12253-016-0170-6. Epub 2016 Dec 28.

PMID:
28032310
18.

JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia.

Zhou C, Martinez E, Di Marcantonio D, Solanki-Patel N, Aghayev T, Peri S, Ferraro F, Skorski T, Scholl C, Fröhling S, Balachandran S, Wiest DL, Sykes SM.

Leukemia. 2017 May;31(5):1196-1205. doi: 10.1038/leu.2016.329. Epub 2016 Nov 14.

19.

Increased phosphorylation of eIF2α in chronic myeloid leukemia cells stimulates secretion of matrix modifying enzymes.

Podszywalow-Bartnicka P, Cmoch A, Wolczyk M, Bugajski L, Tkaczyk M, Dadlez M, Nieborowska-Skorska M, Koromilas AE, Skorski T, Piwocka K.

Oncotarget. 2016 Nov 29;7(48):79706-79721. doi: 10.18632/oncotarget.12941.

20.

Inhibition of human glioma cell proliferation by altered Bax/Bcl-2-p53 expression and apoptosis induction by Rhaponticum carthamoides extracts from transformed and normal roots.

Skała E, Sitarek P, Toma M, Szemraj J, Radek M, Nieborowska-Skorska M, Skorski T, Wysokińska H, Śliwiński T.

J Pharm Pharmacol. 2016 Nov;68(11):1454-1464. doi: 10.1111/jphp.12619. Epub 2016 Oct 2.

PMID:
27696406
21.

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.

Czyż M, Toma M, Gajos-Michniewicz A, Majchrzak K, Hoser G, Szemraj J, Nieborowska-Skorska M, Cheng P, Gritsyuk D, Levesque M, Dummer R, Sliwinski T, Skorski T.

Oncotarget. 2016 Nov 15;7(46):75551-75560. doi: 10.18632/oncotarget.12270.

22.

Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors.

Huang F, Goyal N, Sullivan K, Hanamshet K, Patel M, Mazina OM, Wang CX, An WF, Spoonamore J, Metkar S, Emmitte KA, Cocklin S, Skorski T, Mazin AV.

Nucleic Acids Res. 2016 May 19;44(9):4189-99. doi: 10.1093/nar/gkw087. Epub 2016 Feb 11.

23.

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T.

Blood. 2016 Apr 28;127(17):2131-43. doi: 10.1182/blood-2015-11-681171. Epub 2016 Feb 10.

24.

Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection.

Sullivan K, Cramer-Morales K, McElroy DL, Ostrov DA, Haas K, Childers W, Hromas R, Skorski T.

PLoS One. 2016 Jan 19;11(1):e0147230. doi: 10.1371/journal.pone.0147230. eCollection 2016.

25.

Mitochondrial mutagenesis in BCR-ABL1-expressing cells sensitive and resistant to imatinib.

Blasiak J, Hoser G, Bialkowska-Warzecha J, Pawlowska E, Skorski T.

Acta Biochim Pol. 2016;63(2):365-70. doi: 10.18388/abp.2015_1189. Epub 2016 Jan 12.

26.

A preliminary study of apoptosis induction in glioma cells via alteration of the Bax/Bcl-2-p53 axis by transformed and non-transformed root extracts of Leonurus sibiricus L.

Sitarek P, Skała E, Toma M, Wielanek M, Szemraj J, Nieborowska-Skorska M, Kolasa M, Skorski T, Wysokińska H, Śliwiński T.

Tumour Biol. 2016 Jul;37(7):8753-64. doi: 10.1007/s13277-015-4714-2. Epub 2016 Jan 7.

PMID:
26743778
27.

Doxorubicin Differentially Induces Apoptosis, Expression of Mitochondrial Apoptosis-Related Genes, and Mitochondrial Potential in BCR-ABL1-Expressing Cells Sensitive and Resistant to Imatinib.

Synowiec E, Hoser G, Bialkowska-Warzecha J, Pawlowska E, Skorski T, Blasiak J.

Biomed Res Int. 2015;2015:673512. doi: 10.1155/2015/673512. Epub 2015 Nov 4.

28.

Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers.

Chandramouly G, McDevitt S, Sullivan K, Kent T, Luz A, Glickman JF, Andrake M, Skorski T, Pomerantz RT.

Chem Biol. 2015 Nov 19;22(11):1491-1504. doi: 10.1016/j.chembiol.2015.10.003. Epub 2015 Nov 5.

29.

Reactive Oxygen Species and Mitochondrial DNA Damage and Repair in BCR-ABL1 Cells Resistant to Imatinib.

Blasiak J, Hoser G, Bialkowska-Warzecha J, Pawlowska E, Skorski T.

Biores Open Access. 2015 Jul 1;4(1):334-42. doi: 10.1089/biores.2015.0022. eCollection 2015.

30.

UV Differentially Induces Oxidative Stress, DNA Damage and Apoptosis in BCR-ABL1-Positive Cells Sensitive and Resistant to Imatinib.

Synowiec E, Hoser G, Wojcik K, Pawlowska E, Skorski T, Błasiak J.

Int J Mol Sci. 2015 Aug 5;16(8):18111-28. doi: 10.3390/ijms160818111.

31.

Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation.

Podszywalow-Bartnicka P, Wolczyk M, Kusio-Kobialka M, Wolanin K, Skowronek K, Nieborowska-Skorska M, Dasgupta Y, Skorski T, Piwocka K.

Cell Cycle. 2014;13(23):3727-41. doi: 10.4161/15384101.2014.965013.

PMID:
25483082
32.

[Synthetic lethality as a functional tool in basic research and in anticancer therapy].

Toma M, Skorski T, Sliwiński T.

Postepy Hig Med Dosw (Online). 2014 Sep 3;68:1091-103. Review. Polish.

33.

AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells.

Nieborowska-Skorska M, Flis S, Skorski T.

Leukemia. 2014 Dec;28(12):2416-8. doi: 10.1038/leu.2014.249. Epub 2014 Aug 25. No abstract available.

34.

Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.

Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T.

Blood. 2013 Aug 15;122(7):1293-304. doi: 10.1182/blood-2013-05-501072. Epub 2013 Jul 8.

35.

Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice.

Nieborowska-Skorska M, Hoser G, Hochhaus A, Stoklosa T, Skorski T.

Leukemia. 2013 Nov;27(11):2253-4. doi: 10.1038/leu.2013.123. Epub 2013 Apr 22. No abstract available.

36.

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.

Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, Lange T, Nieborowska-Skorska M, Maier J, Kerstiens L, Koptyra M, Müller MC, Modi H, Stoklosa T, Seferynska I, Bhatia R, Holyoake TL, Koschmieder S, Skorski T.

Blood. 2013 May 16;121(20):4175-83. doi: 10.1182/blood-2012-11-466938. Epub 2013 Mar 29.

37.

Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.

Van Etten RA, Mauro M, Radich JP, Goldman JM, Saglio G, Jamieson C, Soverini S, Gambacorti-Passerini C, Hehlmann R, Martinelli G, Perrotti D, Scadden DT, Skorski T, Tefferi A, Mughal TI.

Leuk Lymphoma. 2013 Jun;54(6):1151-8. doi: 10.3109/10428194.2012.745524. Epub 2012 Dec 10. Review.

38.

BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.

Slupianek A, Falinski R, Znojek P, Stoklosa T, Flis S, Doneddu V, Pytel D, Synowiec E, Blasiak J, Bellacosa A, Skorski T.

Leukemia. 2013 Mar;27(3):629-34. doi: 10.1038/leu.2012.294. Epub 2012 Oct 9.

39.

Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation.

Flis K, Irvine D, Copland M, Bhatia R, Skorski T.

Leuk Lymphoma. 2012 Dec;53(12):2474-8. doi: 10.3109/10428194.2012.696313. Epub 2012 Jun 18.

PMID:
22616753
40.

Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.

Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MM, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, Valent P, Hochhaus A, Hughes TP, van der Kuip H, Sattler M, Wiktor-Jedrzejczak W, Richardson C, Dorrance A, Stoklosa T, Williams DA, Skorski T.

Blood. 2012 May 3;119(18):4253-63. doi: 10.1182/blood-2011-10-385658. Epub 2012 Mar 12.

41.

Genetic mechanisms of chronic myeloid leukemia blastic transformation.

Skorski T.

Curr Hematol Malig Rep. 2012 Jun;7(2):87-93. doi: 10.1007/s11899-012-0114-5. Review.

PMID:
22328017
42.

BCR-ABL1 kinase: hunting an elusive target with new weapons.

Skorski T.

Chem Biol. 2011 Nov 23;18(11):1352-3. doi: 10.1016/j.chembiol.2011.11.001.

43.

BCR-ABL1 kinase facilitates localization of acetylated histones 3 and 4 on DNA double-strand breaks.

Falinski R, Nieborowska-Skorska M, Skorski T.

Leuk Res. 2012 Feb;36(2):241-4. doi: 10.1016/j.leukres.2011.10.007. Epub 2011 Oct 28.

44.

Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.

Mughal TI, Radich JP, Van Etten RA, Quintás-Cardama A, Skorski T, Ravandi F, DeAngelo DJ, Gambacorti-Passerini C, Martinelli G, Tefferi A.

Am J Hematol. 2011 Sep;86(9):811-9. doi: 10.1002/ajh.22097. No abstract available.

45.

Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele.

Virgili A, Koptyra M, Dasgupta Y, Glodkowska-Mrowka E, Stoklosa T, Nacheva EP, Skorski T.

Cancer Res. 2011 Aug 15;71(16):5381-6. doi: 10.1158/0008-5472.CAN-11-0068. Epub 2011 Jun 21.

46.

Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.

Slupianek A, Dasgupta Y, Ren SY, Gurdek E, Donlin M, Nieborowska-Skorska M, Fleury F, Skorski T.

Blood. 2011 Jul 28;118(4):1062-8. doi: 10.1182/blood-2010-09-307256. Epub 2011 Jun 7.

47.

Monoubiquitinated Fanconi anemia D2 (FANCD2-Ub) is required for BCR-ABL1 kinase-induced leukemogenesis.

Koptyra M, Stoklosa T, Hoser G, Glodkowska-Mrowka E, Seferynska I, Klejman A, Blasiak J, Skorski T.

Leukemia. 2011 Aug;25(8):1259-67. doi: 10.1038/leu.2011.91. Epub 2011 Apr 26.

49.

BCR/ABL stimulates WRN to promote survival and genomic instability.

Slupianek A, Poplawski T, Jozwiakowski SK, Cramer K, Pytel D, Stoczynska E, Nowicki MO, Blasiak J, Skorski T.

Cancer Res. 2011 Feb 1;71(3):842-51. doi: 10.1158/0008-5472.CAN-10-1066. Epub 2010 Dec 1.

50.

Chronic myeloid leukemia: mechanisms of blastic transformation.

Perrotti D, Jamieson C, Goldman J, Skorski T.

J Clin Invest. 2010 Jul;120(7):2254-64. doi: 10.1172/JCI41246. Epub 2010 Jul 1. Review.

Supplemental Content

Loading ...
Support Center